Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Consistently High Demand for Immunoglobulin (IgM) Replacement Therapy for Antibody Deficiency to Unlock Substantial Revenue Potential in Primary Immunodeficiency Market During 2020 - 2028, Finds TMR

This image opens in the lightbox

News provided by

Transparency Market Research

04 Jun, 2020, 10:30 GMT

Share this article

Share toX

Share this article

Share toX

  • Players Leverage Advances in Next-generation Sequencing Technologies for Understanding of Pathogenesis of Primary Immunodeficiency Diseases; Tailor-made Primary Immunodeficiency Therapies to Gather Traction
  • Approaches in Targeted Therapies for Genetic Management to Help Reduce Prevalence of Diseases; Gene Therapies to Unlock Vast Potential in the Primary Immunodeficiency Market; Research and Development in DNA sequencing and RNA sequencing

ALBANY, New York, June 4, 2020 /PRNewswire/ -- Advances in gene sequencing, advent of new gene-editing tools, and rapid development of new drugs based on targeted molecular approaches have been the key to the evolution of the primary immunodeficiency market. A wide range of targeted therapies have emerged, most notably rituximab, and monoclonal antibodies have attracted interest of industry players.

A growing body of genome-wide association studies harness potential of next-generation sequencing technologies, expanding the understanding of distinct genetic defects and acute congenital neutropenia.

The global opportunities primary immunodeficiency market stood at US$ 5.7 bn in 2019.

Companies looking for gaining a competitive edge over others should intensively focus on unveiling tailor-made therapies primary immunodeficiency disorders (PIDs), asserted the market analysts at Transparency Market Research. They project the market to clock a CAGR of ~6% from 2020 to 2028.

Download a PDF Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3137

Key Findings of Primary Immunodeficiency Market Report

  • Of all types of PIDs, antibody deficiency accounted for the leading share in primary immunodeficiency market; the prevalence of this types to propel revenues during assessment period
  • Of the various therapy types, immunoglobulin replacement therapy accounted for the top market share in 2019; the segment to rise at higher CAGR than others during assessment period
  • Of all the various regions, North America held the top share in 2019
  • Asia Pacific to show remarkable growth rate from 2020 to 2028

Explore 193 pages of top-notch research, incisive insights, and detailed country-level projections. Primary Immunodeficiency Market (Type: Antibody Deficiency, Cellular Deficiency, and Innate Immune; and End User: Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem Cell and Gene Therapy, and Others [Vaccines, Nutritional Supplements, and Others]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2028 at https://www.transparencymarketresearch.com/report-toc/3137

Primary Immunodeficiency Market: Key Driving Factors and Promising Avenues

  • Industry players in collaboration with the research fraternity have relentlessly pursuing for the management of primary immunodeficiency, opening path to several investigations based on gene therapies in recent years. Surge in investments in gene-editing tools, and incredible advances in next-generation sequencing have helped them develop new drugs in the primary immunodeficiency market. All these will help the market reach ~US$ 9.9 bn by 2028-end.
  • In recent times, lentiviral vector-mediated gene therapies have attracted groundswell of research attention, unlocking new prospects in the primary immunodeficiency market.
  • Players have been incessantly focused on identifying new therapeutic targets for managing primary immunodeficiency. Companies have upped their stakes in genome-wide studies.
  • Strides in omics-based technologies have opened a vast avenue for players in the primary immunodeficiency market. Over the past few decades, the number of identified PIDs, especially in developed countries, has witnessed an alarming rise. To put things in perspective, the IUIS Inborn Errors of Immunity committee admitted that at least 50 new disorders between a short span of three years from 2015 to 2017. This propels rapid advances in immunogenetics.

Purchase the Primary Immunodeficiency Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=3137&ltype=S

Primary Immunodeficiency Market: Regional Assessment

Of all the regions, North America was the dominant market in 2019. For several years the regional market has achieved a remarkable growth trajectory on back of the rising diagnosis of PIDs due to presence of advanced assays and approaches. Companies in the region have also ramped up their investments in omics technology and next-generation sequencing approaches to reduce the morbidity and mortality of PIDs, world over.

Meanwhile, Asia Pacific is a remarkable promising regional market; it held the second-largest share in the global market. The growth in this market is fueled by rapid pace of emerging immunomodulatory agents and strides in genetic studies.

Primary Immunodeficiency Market: Key Impediments

Lack of reimbursement for specialized diagnostic tests makes the testing for primary immunodeficiency costly for populations in numerous nations. In most countries, not more than one IgM therapy is covered. Even in developed regions, the availability of reimbursement is not uniform across all countries.

Inquire for a Sample Copy of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137

The low presence of treatment centers for getting intravenous immunoglobulin (IVIG) is proving to be a hindrance for patient populations, constraining the primary immunodeficiency market. Private insurance policies are also inadequate to cover the high cost.

The primary immunodeficiency market has witnessed several snags due to less than adequate diagnosis rate across the world. Efforts are made by governments and private players to make assays accessible to population at large, which will help improve life expectancy of PID patients considerably.

Global Primary Immunodeficiency Market Segmentation Based on:                                                                                                                       

  • Type
    • Antibody Deficiency
    • Agammaglobulinaemia
    • Common Variable Immune Deficiency
    • Selective IgA Deficiency
    • IgG Subclass Deficiency
    • Others
  • Cellular Deficiency
    • Ataxia Telangiectasia
    • Hyper IgM Syndromes
    • Wiskott-Aldrich Syndrome
    • DiGeorge Syndrome
    • Others
  • Innate Immune
    • Complement Deficiencies
    • Hyper IgE Syndrome
    • Others
  • Treatment type
    • Immunoglobuline Replacement Therapy
    • Antibiotic Therapy
    • Stem cell and Gene Therapy
    • Others (Vaccines, Nutritional Supplements, and Others)
  • Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

Explore Transparency Market Research's award-winning coverage of the global pharmaceutical industry:

Gene Therapy Market - Gene therapy has emerged as a promising treatment option for a large number of diseases such as certain viral infections, certain cancers, and inherited disorders. This factor is likely to work in favor of the global gene therapy market in the years to come.

Intravenous Immunoglobulin Market - Intravenous immunoglobulin market continues to expand at a high growth rate. The market is driven by rise in global prevalence of autoimmune diseases such as primary humoral immunodeficiency (PIDD), multiple sclerosis, immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia, and Kawasaki syndrome.

DNA Sequencing Market - Global DNA sequencing market is projected to achieve an impressive growth rate on the back of its extensive usage in a number of applications and ease of adoption with the emergence of innovative technologies in the field.

Gain access to Market Ngage, an AI-powered, real-time business intelligence that goes beyond the archaic research solutions to solve the complex strategy challenges that organizations face today. With over 15,000+ global and country-wise reports across 50,000+ application areas, Market Ngage is your tool for research on-the-go. From tracking new investment avenues to keeping a track of your competitor's moves, Market Ngage provides you with all the essential information to up your strategic game. Power your business with Market Ngage's actionable insights and remove the guesswork in making colossal decisions.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision."

Contact

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com  
Website: http://www.transparencymarketresearch.com

Logo: https://mma.prnewswire.com/media/1085206/Transparency_Market_Research_Logo.jpg

Modal title

Also from this source

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Over the last year, several companies have announced new semiconductor fabrication sites, especially in the U.S., India, and Europe. These...

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

The market was valued at US$ 6.9 billion in 2022. The Silicon Metal Market Growth is estimated to reach US$ 10.7 billion by the end of 2031,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.